Clinical Trial

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2025 (before its estimated February 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are: * The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis. * The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis. Participants will: * Be treated with either a low-dose or high-dose of JYP0061. * Undergo efficacy and safety evaluations as stipulated in the trial protocol.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-12-05; most recent amendment 2025-03-19.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-11-14
Trial Details
NCT Number NCT06158490
Lead Sponsor Guangzhou JOYO Pharma Co., Ltd
Conditions Moderate-to-severe Atopic Dermatitis
Enrollment 120 participants
Start Date 2023-12-27
Primary Completion 2026-02-10 (estimated)
Study Completion 2026-10-10 (estimated)
Updated on ClinicalTrials.gov 2025-03-20